Agilus Diagnostics Launches Anti-MCV Test for Early RA Detection

The test enhances early detection of rheumatoid arthritis (RA), particularly in patients who test negative for standard diagnostic markers such as anti-CCP and rheumatoid factor (RF).

Agilus Diagnostics, in partnership with Sebia, has launched the Anti-MCV (anti–mutated citrullinated vimentin) antibody test in India. 

Developed by Sebia, the test enhances early detection of rheumatoid arthritis (RA), particularly in patients who test negative for standard diagnostic markers such as anti-CCP and rheumatoid factor (RF).

Rheumatoid arthritis affects around 0.5–1% of the Indian population. This number is expected to rise with growing awareness and improved diagnostic tools. The Anti-MCV test targets autoantibodies against a mutated form of the vimentin protein found in the synovial fluid of RA patients, offering higher sensitivity and specificity for early-stage detection.

“We see Anti-MCV filling a crucial diagnostic gap. Studies show that 10–15% of RA cases missed by anti-CCP can be detected through anti-MCV testing. When patients present with persistent symptoms but test negative for both CCP and RF, anti-MCV offers clinicians a valuable next step,” said Dr. Deepak Sanghavi, senior vice president, operations & chief of Mumbai Reference Lab, Agilus Diagnostics.

The test is particularly beneficial for patients exhibiting clinical symptoms of RA but who do not test positive for traditional markers. Research also indicates that anti-MCV positivity can precede clinical onset by up to 24 months, especially in individuals with a strong family history of RA.

According to clinical data, the combined use of anti-MCV and anti-CCP tests can improve diagnostic sensitivity without compromising specificity, facilitating timely and effective therapeutic decisions.

“Early detection of RA is critical to prevent irreversible joint damage and improve patient quality of life. We are proud to support Agilus in bringing the Anti-MCV test to clinicians and patients across India,” said Dr. Siddhartha Sharma, head – clinical & scientific affairs, Sebia India.

Stay tuned for more such updates on Digital Health News